Get the Stockscreener App
2.84
5.23%
0.17
Agenus Inc stock is traded at $2.84, with a volume of 172.60K.
It is up +5.23% in the last 24 hours and down -37.56% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$2.67
Open:
$2.76
24h Volume:
172.60K
Relative Volume:
0.40
Market Cap:
$62.71M
Revenue:
$156.31M
Net Income/Loss:
$-245.76M
P/E Ratio:
-3.3412
EPS:
-0.85
Net Cash Flow:
$-234.16M
1W Performance:
+1.43%
1M Performance:
-37.56%
6M Performance:
-74.73%
1Y Performance:
-79.37%
1-Day Range:
$2.61
$2.83
1-Week Range:
$2.50
$2.89
52-Week Range:
$2.50
$19.69
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| AGEN | 2.825 | 62.71M | 156.31M | -245.76M | -234.16M | -0.85 |
| VRTX | 449.13 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.49 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.31 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.97 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus Inc. (NASDAQ:AGEN) Receives $10.00 Consensus Target Price from Analysts - MarketBeat
B. Riley Has Negative Outlook for Agenus FY2024 Earnings - MarketBeat
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Agenus stock hits 52-week low at $2.56 amid market challenges - Investing.com Australia
Agenus Chooses Flex Databases for Enhanced Pharmacovigilance Solutions - openPR
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Agenus Inc. (NASDAQ:AGEN) Short Interest Update - MarketBeat
William Blair Weighs in on Agenus' Q4 Earnings (NASDAQ:AGEN) - MarketBeat
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
Biotech Brass Misled Investors About Cancer Drugs, Suit Says - Law360
Agenus Top Brass Sued Over FDA Response to Cancer Drug Trial - Bloomberg Law
Agenus Inc. (NASDAQ:AGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Q3 2024 Agenus Inc Earnings Call - Cbainfo
Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com
Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ... - Yahoo Finance
Agenus Inc. Reports Progress in Immunotherapy Development - TipRanks
Agenus: Q3 Earnings Snapshot - Houston Chronicle
Agenus Reports Third Quarter 2024 Financial Results - citybiz
Agenus (AGEN) Q3 2024 Earnings Call Transcript - AOL
Agenus reports Q3 EPS ($3.08) vs ($3.29) last year - TipRanks
HC Wainwright Issues Pessimistic Forecast for Agenus (NASDAQ:AGEN) Stock Price - MarketBeat
Agenus Inc (AGEN) Q3 2024 Earnings: EPS Miss, Revenue at $25.1M vs. $61.48M Estimate - GuruFocus.com
Agenus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Agenus Q3 Revenue Edges Up Despite Cash Concerns; BOT/BAL Shows Promise in Cancer Trials | AGEN Stock News - StockTitan
Earnings To Watch: Agenus Inc (AGEN) Reports Q3 2024 Result - GuruFocus.com
Agenus stock hits 52-week low at $3.82 amid market challenges - Investing.com India
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024 - Business Wire
Agenus to Showcase Breakthrough Cancer Immunotherapy Data at SITC 2024 Meeting | AGEN Stock News - StockTitan
Agenus (AGEN) Set to Announce Earnings on Tuesday - MarketBeat
AGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Agenus Inc. Invest - GuruFocus.com
Agenus announces director Wiinberg's resignation and advisory role - Investing.com
AGENAgenus Inc. Latest Stock News & Market Updates - StockTitan
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Business Wire
Shareholders that lost money on Agenus Inc.(AGEN) should contact Levi & Korsinsky about pending Class ActionAGEN - PR Newswire
Levi & Korsinsky Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024AGEN - PR Newswire
Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - PR Newswire
Class Action Filed Against Agenus Inc. (AGEN)November 5, 2024 Deadline to Join – Contact Levi & Korsinsky - GlobeNewswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Malaysian Reserve
AGEN Stockholders Have Opportunity to Lead Agenus Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - AccessWire
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming DeadlinesAGEN - PR Newswire
Agenus stock hits 52-week low at $4.17 amid market challenges - Investing.com Australia
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Agenus to Contact Us to Have Their Losses Evaluated Today - GlobeNewswire Inc.
Agenus stock hits 52-week low at $4.17 amid market challenges By Investing.com - Investing.com South Africa
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities F - GuruFocus.com
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Agenus Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationAGEN - PR Newswire
Agenus Inc. Investors: Please contact the Portnoy Law Firm - GlobeNewswire
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):